|
Market Closed -
NYSE
16:00:00 2026-09-01 EDT
|
5-day change | 1st Jan Change | ||
| 0.9955 USD | -2.40% |
|
-7.82% | -26.80% |
| 08-14 | Actinium Pharmaceuticals Expands Manufacturing Capacity for Actimab-A Program | CI |
| 08-14 | Actinium Pharmaceuticals, Inc. Amends Its Investigational New Drug | CI |
Company Valuation: Actinium Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 132.4 | 271.4 | 139.3 | 39.31 | 42.43 | 31.3 | - | - |
| Change | - | 104.97% | -48.69% | -71.77% | 7.94% | -26.23% | - | - |
| Enterprise Value (EV) | 132.4 | 271.4 | 62.58 | 39.31 | 42.43 | 31.3 | 31.3 | 31.3 |
| Change | - | 104.97% | -76.94% | -37.19% | 7.94% | -26.23% | 0% | 0% |
| P/E | -5.01x | -7.77x | -2.78x | -0.99x | -1.25x | 7.11x | -1.47x | -3.21x |
| PBR | 1.81x | - | 3.72x | - | - | - | - | - |
| PEG | - | -0.5x | -0.1x | 0x | 0.1x | -0x | 0x | 0.1x |
| Capitalization / Revenue | 116x | 263x | 1,719x | - | 471x | 2.68x | - | 1.34x |
| EV / Revenue | 0x | 0x | 0x | - | 0x | 2.68x | - | 1.34x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | 13x | -0.84x | -0.76x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | 6.98x | -0.91x | -1.6x |
| EV / FCF | -0x | 0x | -0x | -0x | - | 1.45x | -1.16x | -1.29x |
| FCF Yield | -15.9% | 3.05% | -34.1% | -84.2% | - | 69.1% | -86.3% | -77.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.2 | -1.37 | -1.83 | -1.27 | -1.09 | 0.14 | -0.6767 | -0.31 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 1.144 | 1.03 | 0.081 | - | 0.09 | 11.67 | - | 23.28 |
| EBITDA 1 | -24.44 | -33.4 | -51.13 | -41.31 | -35.43 | 2.4 | -37.1 | -41.1 |
| EBIT 1 | -24.96 | -34.1 | -51.92 | -42.12 | -36.25 | 4.484 | -34.41 | -19.61 |
| Net income 1 | -24.77 | -33.02 | -48.82 | -38.24 | -33.89 | 4.906 | -31.71 | -16.61 |
| Net Debt | - | - | -76.68 | - | - | - | - | - |
| Reference price 2 | 6.0100 | 10.6500 | 5.0800 | 1.2600 | 1.3600 | 0.9955 | 0.9955 | 0.9955 |
| Nbr of stocks (in thousands) | 22,031 | 25,483 | 27,413 | 31,196 | 31,196 | 31,441 | - | - |
| Announcement Date | 3/25/22 | 3/31/23 | 3/29/24 | 3/31/25 | 3/30/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 7.29x | - | - | - | 32.07M | |
| 20.25x | 7.09x | 14.33x | 1.44% | 68.13B | |
| 36.11x | 9.4x | 28.68x | 0.04% | 63.6B | |
| -74.57x | 14.38x | -69.34x | -.--% | 26.6B | |
| -15.53x | 5.87x | -7.38x | -.--% | 25.52B | |
| 26.84x | 5.04x | 16.75x | -.--% | 19.69B | |
| 52.62x | 19.47x | 39.5x | 0.29% | 18.23B | |
| 1309.77x | 37.93x | 827.81x | -.--% | 15.16B | |
| 16.88x | 5.01x | 11.7x | -.--% | 13.54B | |
| -85.52x | 7.83x | -64.86x | -.--% | 12.48B | |
| Average | 129.41x | 12.45x | 88.58x | 0.2% | 26.3B | |
| Weighted average by Cap. | 82.90x | 10.68x | 52.16x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ATNM Stock
- Valuation Actinium Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
